Overview

NCI Definition: A usually slow-growing epithelial neoplasm with ductal differentiation that arises from the exocrine pancreas and grows mostly within the pancreatic ducts. Grossly, it is characterized by the presence of intraductal masses. Morphologically, there is proliferation of mucin-producing cells within the pancreatic ducts, intraductal accumulation of mucin, and a papillary growth pattern. It may be associated with the presence of an invasive carcinoma. It usually occurs in older patients. Signs and symptoms include epigastric pain, weight loss, jaundice, chronic pancreatitis, and diabetes mellitus. [1]

Pancreatic intraductal papillary-mucinous neoplasms most frequently harbor alterations in KRAS, GNAS, BRAF, TP53, and KLF4 [2].

Most Commonly Altered Genes in Pancreatic Intraductal Papillary-Mucinous Neoplasm

KRAS Mutation, GNAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, and GNAS R201H are the most common alterations in pancreatic intraductal papillary-mucinous neoplasm [2].

Top Alterations in Pancreatic Intraductal Papillary-Mucinous Neoplasm

Disease Details

Synonyms
Pancreatic Intraductal Papillary-Mucinous Tumor, IPMN, Pancreatic IPMN
Parent(s)
Pancreatic Intraductal Neoplasm
Children
Pancreatic Intraductal Papillary-Mucinous Neoplasm with Low Grade Dysplasia, Pancreatic Intraductal Papillary-Mucinous Neoplasm with an Associated Invasive Carcinoma, Pancreatic Intraductal Papillary-colloid Carcinoma, and Pancreatic Intraductal Papillary-Mucinous Neoplasm with High Grade Dysplasia
OncoTree Name
Intraductal Papillary Mucinous Neoplasm
OncoTree Code
IPMN

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.